Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XXII - US90137F5098 - Common Stock

0.77 USD
+0.01 (+1.17%)
Last: 12/31/2025, 8:00:02 PM
0.751 USD
-0.02 (-2.47%)
After Hours: 12/31/2025, 8:00:02 PM
Fundamental Rating

2

Overall XXII gets a fundamental rating of 2 out of 10. We evaluated XXII against 8 industry peers in the Tobacco industry. While XXII seems to be doing ok healthwise, there are quite some concerns on its profitability. XXII is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.
In the past year XXII has reported a negative cash flow from operations.
In the past 5 years XXII always reported negative net income.
In the past 5 years XXII always reported negative operating cash flow.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

XXII's Return On Assets of -29.02% is on the low side compared to the rest of the industry. XXII is outperformed by 75.00% of its industry peers.
With a Return On Equity value of -44.51%, XXII perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -29.02%
ROE -44.51%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XXII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XXII has more shares outstanding
Compared to 5 years ago, XXII has more shares outstanding
XXII has a better debt/assets ratio than last year.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

XXII has an Altman-Z score of -17.14. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
XXII has a worse Altman-Z score (-17.14) than 62.50% of its industry peers.
XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.14
ROIC/WACCN/A
WACC7.91%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

XXII has a Current Ratio of 2.17. This indicates that XXII is financially healthy and has no problem in meeting its short term obligations.
XXII has a better Current ratio (2.17) than 62.50% of its industry peers.
A Quick Ratio of 1.90 indicates that XXII should not have too much problems paying its short term obligations.
XXII has a better Quick ratio (1.90) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.9
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

XXII shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.51%, which is quite impressive.
XXII shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.81%.
XXII shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.15% yearly.
EPS 1Y (TTM)96.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.09%
Revenue 1Y (TTM)-34.81%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-32.54%

3.2 Future

XXII is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.08% yearly.
The Revenue is expected to decrease by -1.55% on average over the next years.
EPS Next Y90.86%
EPS Next 2Y41.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-46.02%
Revenue Next 2Y-1.55%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XXII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400

4.3 Compensation for Growth

A more expensive valuation may be justified as XXII's earnings are expected to grow with 41.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XXII!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (12/31/2025, 8:00:02 PM)

After market: 0.751 -0.02 (-2.47%)

0.77

+0.01 (+1.17%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners3.49%
Inst Owner Change634.93%
Ins Owners4.39%
Ins Owner Change1.43%
Market Cap5.38M
Revenue(TTM)18.07M
Net Income(TTM)-9.39M
Analysts82.86
Price Target9.18 (1092.21%)
Short Float %2.52%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.61%
Min EPS beat(2)-114.86%
Max EPS beat(2)-42.36%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.4%
Min Revenue beat(2)-26.42%
Max Revenue beat(2)-6.37%
Revenue beat(4)1
Avg Revenue beat(4)-16.07%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-24.87%
Revenue beat(12)2
Avg Revenue beat(12)-26.19%
Revenue beat(16)3
Avg Revenue beat(16)-19.85%
PT rev (1m)28.57%
PT rev (3m)80%
EPS NQ rev (1m)-122.73%
EPS NQ rev (3m)-122.73%
EPS NY rev (1m)-46.77%
EPS NY rev (3m)-46.77%
Revenue NQ rev (1m)-12.77%
Revenue NQ rev (3m)-12.77%
Revenue NY rev (1m)-4.18%
Revenue NY rev (3m)-4.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-479.95
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-2.15
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.59
BVpS3.02
TBVpS2.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.02%
ROE -44.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.97%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.17
Quick Ratio 1.9
Altman-Z -17.14
F-Score4
WACC7.91%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.09%
EPS Next Y90.86%
EPS Next 2Y41.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.81%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-32.54%
Revenue Next Year-46.02%
Revenue Next 2Y-1.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.53%
OCF growth 3YN/A
OCF growth 5YN/A

22ND CENTURY GROUP INC / XXII FAQ

What is the fundamental rating for XXII stock?

ChartMill assigns a fundamental rating of 2 / 10 to XXII.


What is the valuation status of 22ND CENTURY GROUP INC (XXII) stock?

ChartMill assigns a valuation rating of 1 / 10 to 22ND CENTURY GROUP INC (XXII). This can be considered as Overvalued.


Can you provide the profitability details for 22ND CENTURY GROUP INC?

22ND CENTURY GROUP INC (XXII) has a profitability rating of 0 / 10.